BMCC-2022-V03

Targeted Antigen Delivery System

BMCC

Targeted Antigen Delivery System

未定中標題
BMCC Targeted indication

Vaccine or cancer immunotherapy

BMCC Status

Preclinical study

BMCC Key features
  • High safety profile
  • Highly immunogenic protein
  • The platform technology could be applied to different vaccines products.
BMCC Market

The fusion protein made using this technology can be used alone as vaccine candidates or formulated with adjuvant. In vaccination, subunit vaccines are likely the new generation vaccines because of their safety and efficiency. This technology has been applied in survivin subunit vaccine for cancer immunotherapy and Zika subunit vaccines.

We expect this technology to be used in the development of new and better vaccines, especially for the unment medical need disease areas.

MODE OF ACTION

Dendritic cells express various Fcγ receptors (FcγRs), which mediate internalization of antigen-antibody complexes and regulate immune responses. Targeting of antigen to dendritic cells via FcγRs potentially constitutes an effective strategy for modulation of antigen-specific immune responses. Formyl peptide receptor-like inhibitory protein (FLIPr), secreted by Staphylococcus aureus, can bind to various Fcγ receptors. Therefore, antigen-FLIPr fusion proteins can guide antigens to FcγR and induce potent immune responses.

 

EXPERIMENTAL RESULTS

Target Verification

Fusion antigen with FLIPr can enhance antigne-specific CD4+ and CD8+ T cell responses

Target Validation

NA

INTELLECTUAL PROPERTY

Pending patent application

SELECTED PUBLICATIONS

Manuscript in preparation

BUSINESS OPPORTUNITY

License and/or Collaboration and Sponsored Research

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊